New Study Shows Ashwagandha Supports Women’s Stress, Sleep and Brain Health

Why It Matters

Balancing cortisol while extending activity addresses a key gap in stress‑relief supplements, offering women a scientifically backed option for holistic health during hormonal transitions.

Key Takeaways

• Shoden balanced cortisol instead of merely suppressing it.
• Activity persisted up to 24 hours, double typical ashwagandha extracts.
• Standardized to 35% withanolide glycosides, boosting bioavailability.
• Study showed improvements in sleep quality, mood and mental clarity.
• Arjuna will test Shoden in perimenopausal and menopausal women.

Pulse Analysis

The global adaptogen market has surged as consumers seek natural ways to manage stress, yet the industry remains fragmented by varying extraction methods and potency claims. Ashwagandha, a cornerstone herb, often suffers from inconsistent bioavailability, prompting regulators—particularly in India—to tighten rules around leaf‑based products. In this climate, Arjuna Natural’s Shoden extract distinguishes itself by delivering a 35 % withanolide glycoside profile, a benchmark that promises more reliable absorption and sets a new standard for quality‑focused manufacturers.

The three‑arm clinical trial enrolled 120 women aged 30 to 59 and measured cortisol, sleep, stress, mood and cognitive function over eight weeks. Unlike many ashwagandha products that blunt cortisol peaks, Shoden achieved a true hormonal balance, preserving the hormone’s essential daytime role while reducing evening spikes. Pharmacokinetic testing revealed active compounds remained detectable for up to 24 hours, roughly three times longer than conventional extracts that fade after six to seven hours. Participants reported better sleep continuity, sharper focus and reduced brain‑fog, suggesting a holistic benefit profile beyond simple stress relief.

Arjuna’s next phase targets perimenopausal and menopausal cohorts, groups in which cortisol dysregulation and sleep disturbances are especially prevalent. By extending the evidence base, the company aims to position Shoden as a clinically validated option for women navigating hormonal transitions, a market segment projected to exceed $10 billion in the United States alone. Meanwhile, the Indian leaf‑restriction underscores a broader push for plant‑part specificity, likely prompting other supplement makers to adopt higher‑standardization extracts. For consumers, the study reinforces the importance of choosing products with transparent potency metrics rather than generic ashwagandha powders.